Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with ... aged 18 years and older with a body mass index of at least 30kg/m 2 and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

as it can provide a 15% to 20% reduction in body weight, compared to 10% to 15 % with semaglutide and 5% to 10% with liraglutide. However, these medications can work differently for different ...

semaglutide 2.4mg, or placebo once weekly for 68 weeks. The primary endpoint was the change from baseline in body weight at week 68. When evaluating under the trial product estimand, findings ...

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to ...

semaglutide use led to lower insulin requirements and increased weight loss. It showed greater benefits in participants with ...

When evaluating the effects of treatment if all people adhered to treatment 1 from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7 ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...